100 + INNOVATIONS
Cure Leukodystrophy – Advancing Gene Therapies for Rare Childhood Brain Diseases
Targeted gene therapy offering hope for children with devastating brain diseases
Learn More
Research Project
Proof-of-concept
Challenge
Children with leukodystrophies face rapid neurological decline, with no effective treatments available. Families, clinicians and health care systems struggle to manage progressive disability and high-care needs. The absence of disease-modifying therapies creates an urgent need for solutions that can halt or reverse disease progression and improve long-term outcomes.
Solution
This project develops a gene therapy that combines genetic modifications to enhance transgene expression and reduce immunogenicity with optimised promoter elements for precise activity in target cells. Using advanced Adeno-associated virus gene expression vectors for targeted central nervous system delivery, the approach directly addresses the root cause of leukodystrophies. Tested in accurate disease models, it demonstrates the safe and efficient rescue of pathology, offering a clear pathway for clinical translation.
Target customers / end-users
• families and patients seeking effective therapies
• clinicians treating childhood leukodystrophies
• health care providers and systems aiming to reduce disease burden.
Progress
• efficacy and safety demonstrated in preclinical models
• more than AU $ 3m in research grant funding
• disseminated through peerreviewed publications and national media, boosting visibility and stakeholder engagement.
TRL 4
Healthy Living
The project leverages advanced gene optimisation and cutting-edge viral vector delivery to correct currently untreatable childhood whitematter diseases. Demonstrated success in preclinical models, supported by strong funding traction, drives momentum towards transformative therapies for children affected by these devastating neurological conditions.
• 81